Intervention not reported
≥ 50% reduction in seizure frequency (adults) · people with drug‐resistant focal epilepsy
The intervention probably leads to higher ≥ 50% reduction in seizure frequency (adults) (moderate certainty).
1 finding from 1 review
Intervention not reported
≥ 50% reduction in seizure frequency (children aged 6–18 years) · people with drug‐resistant focal epilepsy
The intervention showed no clear difference in ≥ 50% reduction in seizure frequency (children aged 6–18 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Freedom from seizures · people with drug‐resistant focal epilepsy
The intervention probably leads to higher freedom from seizures (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (any reason) · people with drug‐resistant focal epilepsy
The intervention showed no clear difference in treatment withdrawal (any reason) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (adverse effect) · people with drug‐resistant focal epilepsy
The intervention probably leads to higher treatment withdrawal (adverse effect) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects · people with drug‐resistant focal epilepsy
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain)
1 finding from 1 review
no estimate extracted
2746 participants
Moderate
FUNCTIONAL LIMITATIONS
1 finding from 1 review
no estimate extracted
2942 participants
Moderate
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale)
1 finding from 1 review
no estimate extracted
6295 participants
Low
FUNCTIONAL LIMITATIONS
1 finding from 1 review
no estimate extracted
6004 participants
Moderate
*The anticipated absolute effects without exercise come from the range of outcomes at
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
12MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
3MSC: change in 3MSC rates (stairs/min) from baseline · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
6MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Respiratory tests: absolute change from baseline in FVC (L) · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Cardiac function  · children and adults with mucopolysaccharidosis type VI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
GAG level: change in urinary GAG level from baseline ųg/mg creatinine · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
AEs: drug‐related AEs · children and adults with mucopolysaccharidosis type VI
It is very uncertain whether the intervention changes AEs: drug‐related AEs (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with epilepsy
1 finding from 1 review
Adverse effects (cardiac) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).
1 finding from 1 review